Twist Bioscience Corp 2024年度报告

☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR Twist Bioscience Corporation 46-2058888(I.R.S. EmployerIdentification No.) Securities Registered Pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☒No☐ Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes☐No☒ Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that theRegistrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that the Registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large acceleratedfiler,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer Non-accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant toSection 13(a) of the Exchange Act.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financialstatements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevantrecovery period pursuant to § 240.10D-1(b).☐ As of March 31, 2024, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of shares of common stock held by non-affiliates of the registrant was approximately$1.92 billion based upon the closing sale price on the Nasdaq Global Select Market reported for such date. The number of shares of the Registrant’s common stock outstanding as of November13, 2024, was 59,356,440. DOCUMENTS INCORPORATED BY REFERENCE Portions of the Registrant’s definitive proxy statement to be filed in connection with its 2024 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K. TWIST BIOSCIENCE CORPORATIONANNUAL REPORT ON FORM 10-KFOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2024 TABLE OF CONTENTS PART I Item 1.BusinessItem 1A.Risk factorsItem 1B.Unresolved staff commentsItem1C.CybersecurityItem 2.PropertiesItem 3.Legal proceedingsItem 4.Mine safety disclosures PART II Item 5.Market for registrant’s common equity, related stockholder matters and issuer purchases of equity securitiesItem 6.[Reserved]Item 7.Management’s discussion and analysis of financial condition and results of operationsItem 7A.Quantitative and qualitative disclosures about market riskItem 8.Consolidated financial statements and supplementary dataItem 9.Changes in and disagreements with accountants on accounting and financial disclosureItem 9A.Controls and proceduresItem 9B.Other informationItem 9C.Disclosure regarding foreign jurisdiction that prevent inspections PART III Item 10.Directors, executive officers and corporate governanceItem 11.Executive compensationItem 12.Security ownership of certain beneficial owners and management and related stockholder mattersItem 13.Certain relationships and related transactions, and director independenceItem 14.Principal accounting fees and services PART IV Item 15.Exhibits, financial statement schedulesItem 16.Form of 10-K summary SIGNATURES Forward-looking statements This Annual Report on Form 10-K for the fiscal year ended September 30, 2024, or Form 10-K, contains forward-looking statements within the meaning ofSection 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or theExchange Act. These statements relate to, among other matters, plans for product development and licensing to third parties, plans and timeframe for thecommercial development of DNA data storage capabilities, expectations regarding market penetration, anticipated customer conversions to our products,plans to expand in the inte